- Acid aGlucosidase
- Activation of FIX Zymogen
- Additional Safety Concerns
- Adverse Reactions and Warnings - 2 3
- Advisory Committee Preparation and Execution
- Alteplase
- Ancrod
- Ancrod Development
- Antithrombotic Activity of APC
- Antithrombotic Mechanism
- APC Mechanism and Sepsis
- APC Mechanisms of Action
- At
- Biochemical Aspects
- Biochemical Characteristics
- Biochemical Function in GAG Metabolism
- Biochemical Properties - 2
- Biochemistry
- Biochemistry and Genetics of Recombinant aLIduronidase - 2
- C
- Catalytic Activity
- Catalytic Mechanism
- Cell Banking and Stability of the Cell Line
- Cell Culture and Perfusion Process
- Cell Line Identification
- Characterization of Protein and Carbohydrate
- Clinical Deficiency of aLIduronidase and MPS I
- Clinical Development of Drotrecogin Alfa Activated for Severe Sepsis
- Clinical Evaluation 11571 Preclinical Studies
- Clinical Safety
- Clinical Studies - 2
- Clinical Trials
- Conclusions - 2 3
- Contents - 2 3 4 5 6 7 8 9 10 11 12 13
- Contributors
- Determination of Activity
- Development of an rFIX Production Line
- Development of Ceredase
- Development of rFVIIa as a Universal Hemostatic Agent
- Development of rhAPC
- Developmental History of the Enzyme 1051 Preclinical Development
- Discovery of Correction In Vitro Uptake and Treatment of MPS I
- Nase I in NonCF Respiratory Diseases
- Nase I in Wound Healing and Cancer
- Early Attempts at Therapy
- Early Production of rhIDU
- Early Treatments
- Efficacy in Models of Ischemic Injury
- Enzyme Composition Synthesis and Biochemical Action 12211 Protein and Gene Sequence and Structure
- Figure 101 - 2
- Figure 102
- Figure 103 - 2
- Figure 104
- Figure 105
- Figure 106
- Figure 111
- Figure 112 - 2
- Figure 113
- Figure
- Figure 121
- Figure 122
- Figure 123
- Figure 124 - 2
- Figure 131
- Figure 132
- Figure 134
- Figure 135 3 4 5
- Figure 22 6 7 8 9 10 11 12 13 14 15 16
- Figure 53 17 18 19 20 21 22 23 24 25
- Figure 77
- Figure 811 26
- FIX Modification
- Formulation and Administration Aspects
- FVII Deficiency
- Gaucher Disease
- Gene Therapy for Hemophilia B
- Gj Vc
- Gj Vi
- Glanzmanns Thrombasthenia
- Hemophilia Patients with Inhibitors
- High Purity pdFIX Products
- Hyaluronidase
- Indications for which Factor VIIa is Approved
- Info - 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
- Intracellular Trafficking and Uptake Via M6PR
- Introduction - 2
- Introduction and Overview 3 4 5
- K
- Manifestations of the Spectrum of Mps I Disease
- Manufacture and Composition - 2 3
- Manufacturing Process
- Mechanism of Action of rFVIIa
- Mechanistic Observations from the Clinical Experience
- Molecular Basis
- Mutations in aLlduronidase in MPS I
- N - 2
- N N
- NLinked Carbohydrate Structure
- NLinked Glycosylation
- Nonresponders and Inhibition of DNase I by Actin
- Nonviral Vectors
- OLinked Glycosylation
- On O
- Pancreatin
- Pathophysiology of MPS I
- Pharmacokinetics in Patients
- Polymorphisms
- Preface
- Production and Stability of rhDNase I
- Production of Acid aGlucosidase for Therapeutic
- Production of Streptokinase
- Prospects
- Protein Domain Structure of FIX
- Purification
- Purification and Characterization of Recombinant Produced Human APC
- Purification of Highly Purified High Uptake rhIDU
- Purification of rFIX
- Purity and Safety
- Q
- Quality Control Evaluations
- Rationale and Clinical Results
- Rationale for Enzyme Therapy in MPS I
- Reductions in Measures of Storage
- References - 2 3 4 5 6
- Regulatory Approval
- Regulatory Strategies and Challenges with Surrogate Endpoints
- Results from Finalized Trials Outside the Current Indication
- Reteplase
- RFIX Biochemical Properties and Characterization
- RFIX Formulation
- RFIX Production Cell Line
- RhAPC Derivatives
- Role of Protein C Pathway in Sepsis
- S
- S61
- Safety
- Shiprec
- Sources of Urokinase
- Steps to Increase Safety of Blood Derived Clotting Factor Products
- Streptokinase
- Studies of ERT in Canine MPS I
- Study Results in Reducing Lysosomal Storage
- Study Results in the Clinical Manifestations
- Study Results in the Primary Endpoints
- Summary and Conclusions
- Superoxide Dismutase
- Table - 2 3 4 5 6 7 8 9
- Tenecteplase
- Testicular Type Hyaluronidases
- Therapeutic Applications - 2 3
- Therapeutic Efficacy
- Therapeutic Hyaluronidases
- Therapeutic Rationale for Sepsis 4431 Sepsis Pathophysiology
- Therapeutic Uses
- Three Dimensional Structure of FVIIa and its Relation to Function
- Treatment of Hemophilia B
- University of Limerick Limerick Ireland
- Urokinase
- Use of Clinical Endpoints in a Novel Disease Target
- Viral Vectors for Hemophilia B Gene Therapy
- X
- Ynsgkleefvqgnlerecmeekcsfeearevfentertte Fwkqyv Dgdq 5